---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038544"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:18:52.341997+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals sells 250 Series B Preferred shares for $250,000 in fourth closing under SPA

## Summary
- Sold 250 Series B Preferred shares to institutional accredited investor for $250,000; effective price at 10% discount to $1,100 stated value.
- Total 750 of 1,000 possible Series B shares sold to date; 250 remain available for future sale.
- Full conversion at $0.15 floor price yields 1,833,333 common shares; shareholder approval obtained for >19.99% issuance.
- Issuance exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.

## SEC filing metadata
- accession: 0001493152-24-038544
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224038544/0001493152-24-038544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224038544/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038544
- JSON: https://secwatch.observer/filing/0001493152-24-038544.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.